The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing approval of Novartis’ (NYSE:NVS) Piqray (alpelisib) for the treatment of locally advanced or metastatic breast cancer with a PIK3CA mutation.
A final decision from the European Commission usually takes ~60 days.
https://seekingalpha.com/news/3578599-european-advisory-group-backs-novartis-alpelisib-for-certain-type-of-breast-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.